Protalix BioTherapeutics, Inc. 8-K

What Happened
Protalix BioTherapeutics, Inc. (PLX) announced via Form 8-K on January 5, 2026 that it issued a press release containing a letter to its stockholders. The press release and letter were furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The filing was signed by Dror Bashan, President and CEO.

Key Details

• Filing date: January 5, 2026 (Current Report on Form 8-K).
• Item reported: 7.01 — Regulation FD Disclosure; Exhibit 99.1 is the press release/stockholder letter.
• The company states the furnished information is not “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into registration statements (General Instruction B.2 of Form 8‑K).
• Report was executed/signed by Dror Bashan, President & CEO.

Why It Matters
This 8-K is a routine disclosure to ensure fair public communication (Regulation FD) — it notifies investors that Protalix has directly communicated a letter to stockholders. The filing does not report earnings, executive changes, mergers, or other material financial actions; it is informational and furnished (not “filed”), which limits incorporation and certain liabilities under the securities laws. Investors should read the attached press release/letter (Exhibit 99.1) for any company updates or guidance referenced therein.